Boston, Massachusetts, United States
Track record of delivery of biopharmaceuticals including Mabs, vaccines and therapeutic proteins with >30 candidate drugs entering development in different therapeutic areas. Led many aspects of start-up company, including business, investor and analyst meetings, strategic planning, recruiting scientists and developing appropriate infrastructure. Managed groups up to 350 employees and built and retained teams of strong scientific skills and managerial resilience. Executive level positions at CAT (UK), Astra Zeneca (UK/SE), Affitech (DK), Actigen (UK) and Agenus (USA/UK). Board level positions CAT, Affitech AS, Actigen, ExpreS2ion A/S (DK). Big believer in people and the power of teams.
Scientific leadership and drive at TrisaQ, an early-stage, venture-backed biopharmaceutical company targeting renal diseases. The company’s objective is to discover, develop, and commercialize products addressing both rare and non-rare renal diseases. As we move toward clinical trials, TrisaQ's technology has the potential to restore or preserve the function of diseased kidney cells. Our objective is to materially transform the therapy of renal diseases; an area of significant unmet need.
responsible for several development project teams for immunomodulatory antibody compounds managing JSCs for collaborative projects CSO & Head R&D Affitech A/S Board member and Managing Director Affitech Research AS Board member of ExpreS2ion technologies, Copenhagen